Alan S. Roemer 99MBA has been appointed the Chief Financial Officer of Zelos Therapeutics

Zelos is focused on the development of bone disease therapies covering osteoporosis, fracture prevention & repair, multiple myeloma, stem cell transplantation and renal bone disease. To date, Zelos has received funding from top-tier biotech investors, including Alta Partners, Prospect Ventures, Frazier Healthcare, VenGrowth and SROne. Zelos plans to initiate a Phase 3 trial of ZT-031 for the prevention of vertebral fractures in postmenopausal women with severe osteoporosis.

For reference, visit the Zelos website.